<DOC>
	<DOCNO>NCT01312922</DOCNO>
	<brief_summary>The overall objective trial demonstrate clinically relevant superior antidepressant efficacy fix dose combination PNB01 ( low dose pipamperone citalopram ) reference antidepressant treatment citalopram alone , low dose psychoactive pipamperone alone patient moderate severe Major Depressive Disorder . This study specifically design assess patient relate outcome ( PRO ) parameter use Interactive Voice Response System ( IVRS ) via telephone .</brief_summary>
	<brief_title>Pipamperone/Citalopram ( PNB01 ) Versus Citalopram ( CIT ) Versus Pipamperone ( PIP ) Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>This international , double-blind , centrally randomize ( stratify ) , multicenter study 555 patient suffer moderate severe MDD 40 site USA , Germany Canada . Eligible out-patients treat daily ( QD ) fix dose either PNB01 ( PIP 15 mg / CIT 20 mg ( Week 1 ) - PIP 15 mg / CIT 40 mg ( Week 2-10 ) ) , CIT alone ( CIT 20 mg ( Week 1 ) - CIT 40 mg ( Week 2-10 ) PIP 15 mg alone ( Week 1-10 ) 1:1:1 ratio double-blind fashion 10 week . Study visit conduct 1 , 2 , 3 , 4 , 6 , 8 10 week study treatment initiation . Possible withdrawal effect assess 1 week study treatment withdrawal . A blood sample pharmacokinetic analysis collect draw blood routine biochemistry . Patients provide write informed consent participate study ask provide consent participate also non-mandatory pharmacogenetic study . Patient related outcomes collect electronically ( ePRO ) study visit prior visit investigator use Interactive Voice Response System ( IVRS ) via telephone . Patients wish choose discontinue study treatment prematurely encourage continue provide score , safety data medication take , schedule study end , telephone .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Pipamperone</mesh_term>
	<criteria>1 . Patient inform give ample time opportunity think her/his participation give her/his write informed consent . 2 . Patient understands investigational nature trial willing able comply trial requirement . 3 . Patient male female , age ≥ 18 year . 4 . Patient MDD accord DSM IVR criterion existence depress mood ( DSMIVR Crit . A1 ) loss interest/anhedonia ( DSMIVR Crit . A2 ) confirm MINI , last least 4 week longer 18 month ( 78 week ) current episode , cause significant functional impairment ( DSMIVR MDD C criterion ) . 5 . CGIS rating least 4 minimum MADRS total score 26 use IVRS ePRO Baseline . 1 . Patient pregnant , nursing , woman childbearing potential surgically sterile , 2 year postmenopausal , consistently use 2 combined effective method contraception ( include least 1 barrier method ) , unless sexually abstinent . 2 . Existence Mood Disorder psychotic feature and/or high suicidality risk , confirm MINI . 3 . Concomitant diagnosis additional primary Axis I disorder presence follow comorbid disorder : ( Hypo ) manic episode , Panic Disorder ( limited symptom attack allow ) , Obsessive Compulsive Disorder , Posttraumatic Stress Disorder , Alcohol dependence , Substance abuse and/or dependence , Psychotic Disorder , Eating Disorder , General Anxiety Disorder , confirm MINI . 4 . Concomitant diagnosis primary Axis II disorder . 5 . Patient hospitalize . 6 . Patient clinically relevant renal dysfunction ( e.g . GFR &lt; 60mL/min ) . 7 . Patient hepatic dysfunction ( total bilirubin &gt; 2.0mg/dL alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great 2 time upper limit reference range ) . 8 . Patient malignant neoplastic disease , document history epilepsy ( juvenile convulsion except ) document , opinion investigator , clinically relevant risk bleeding ( eg . severe bleed disorder , treatment warfarin , … ) . 9 . Patient document history concomitant diagnosis significant risk cardiac arrhythmia dysrhythmia , include QTc interval ≥500 m Baseline . 10 . Patient medical psychiatric condition , opinion investigator , jeopardize would compromise patient 's ability participate trial would interfere trial assessment . 11 . Patient document alcohol drug abuse , positive standard screen alcohol drug ( include benzodiazepine opioids ) . 12 . Patient receive , past 7 day treatment psychoactive drug prior randomization , include typical atypical antipsychotic , hypnotic , antidepressant , anxiolytic drug , anticonvulsive therapy , opioids , monoamine oxidase ( MAO ) inhibitor , sedative antihistamine , psychostimulants amphetamine , dopamine D2 receptor antagonist , butyrophenones , metoclopramide , lithium , anticonvulsant , benzodiazepine , barbiturate . If patient receive therapy , washout period least 7 day prior baseline require inclusion trial ( except fluoxetine : 4 week , St John 's Wort MAO inhibitor : within 2 week ) . 13 . Concomitant treatment diuretic , QT prolongation drug , dopamine agonist . 14 . Resistant depression define failed respond either : a/ 2 previous antidepressant adequate dose administer least 4 week current episode ; b/ augmentation therapy atypical antipsychotic drug 15 . Electroconvulsive therapy ( ECT ) repetitive Transcranial Magnetic Stimulation therapy ( rTMS ) within last 6 month ; Vagus Nerve Stimulation ( VNS ) Deep Brain Stimulation ( DBS ) ever . 16 . Formal psychotherapy alternative treatment 1 week prior study . 17 . Patient participate another trial investigational agent ( include medical device ) within last 3 month prior baseline currently participate another trial investigational drug . 18 . Known hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>